Kantonsspital St.Gallen
login

A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Tobias Silzle, Christoph Driessen, Martin Fehr, Felicitas Hitz & Thomas Lehmann

abstract A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
   
type of project clinical studies
status scheduled
start of project 2021
end of project 2030
study design Phase III
responsible person Dr. med. Tobias Silzle